Peripheral Biomarker Based Combinatorial Early Diagnostics for Dementia (CombiDiag)

CombiDiag DN旨在为阿尔茨海默病（一种主要的痴呆症）的早期阶段开发一种基于人工智能数据驱动的外周生物标志物的组合诊断方案，并为这一跨学科领域培养新一代研究员。痴呆症是一种毁灭性的老年疾病，是我们一生面临的挑战，也是联合国可持续发展目标和“地平线欧洲”所列出的社会挑战之一。CombiDiag应对了这一挑战，建立了一个急需的DN，以开展微创和成本效益高的外周生物标志物的综合研究，包括来自血液、尿液和唾液的体液标志物，以及来自语言、运动功能和睡眠的数字标志物，用于开发组合早期AD诊断。该联盟由欧洲、美国、加拿大和中国的9所学术机构和8所非学术机构组成。它汇集了全球领先的学术和行业专家，建立了一个三级研究和培训平台，培训新一代研究员，将早期阿尔茨海默病诊断研究提升到一个新的水平。研究员将在Vitae研究员发展框架下接受培训，该框架与CombiDiag平台进行创新结合，培养三级科学和可转移技能、个人素质、创造性思维和商业思维。DN在发现AD周边生物标志物、检测技术、人工智能/数据驱动技术、临床验证和整合到试验设计方面拥有高度创新的研究计划。CombiDiag研究的进展将使初级保健层面的病例发现工具能够帮助实现改进的药物发现、疾病改善治疗、预防策略和对AD的护理提供。CombiDiag将提供10名高技能、有创造力和创业精神的研究员，为他们在学术界或工业界的成功职业生涯铺平道路，以确保AD带来的医疗和社会挑战得到满足。

CombiDiag DN aims to develop an AI-data-driven peripheral biomarker based combinatorial diagnostic protocol for early stages of Alzheimers disease (AD), a major form of dementia, and to train a new generation of fellows for this interdisciplinary field. Dementia, a devastating disease of older age, is the challenge of our lifetime and one of the Societal Challenges listed by the UN Sustainable Development Goals and Horizon Europe. CombiDiag responds to this challenge to establish a much-needed DN to carry out an integrated study of minimally invasive and cost-effective peripheral biomarkers, including body fluid markers from blood, urine and saliva, and digital markers from speech, motor functions and sleep for developing the combinatorial early AD diagnostics. The consortium comprises nine academic and eight non-academic institutions across Europe, USA, Canada, and China. It synergises leading academic and industrial experts worldwide to build a triple-i research and training platform for the training of a new generation of Fellows to take early AD diagnostic research to a new level. Fellows will be trained under the Vitae Researcher Development Framework innovatively combined with the CombiDiag platform for triple-i scientific and transferable skills as well as personal quality, creative thinking, and business mind-set. The DN has a highly innovative research programme for the discovery of peripheral AD biomarkers, detection techniques, AI/data driven technology, clinical validation, and integration into trial designs. The advances in CombiDiag research will enable a case finding tool at primary care level for helping achieve improved drug discoveries, disease-modifying treatments, preventive strategies and care provision for AD. CombiDiag will deliver 10 highly-skilled, creative and entrepreneurial Fellows, setting them on a path to successful careers in academia or industry to ensure that the medical and societal challenges imposed by AD are met.